Lynk Pharmaceuticals Begins Phase II Trials for Vitiligo Drug LNK01004

The randomized, double-blind study is spearheaded by Professor Jianzhong Zhang and Professor Cheng Zhou of Peking University People's Hospital. Unlike traditional JAK inhibitors, LNK01004 is engineered for skin-restricted distribution. By minimizing systemic exposure while maintaining potent inhibitory activity against inflammatory cytokine pathways, the drug seeks to balance therapeutic efficacy with a favorable safety profile.

Dr. Henry Wu, overseeing the research program, noted that the treatment addresses both the physical depigmentation and the psychological burden associated with vitiligo. Lynk Pharmaceuticals intends to use the data generated from this trial to support subsequent pivotal studies. Beyond vitiligo, the company is testing the ointment for chronic hand eczema, part of a broader development strategy that leverages AI-assisted design and protein degradation technologies to treat autoimmune and inflammatory conditions.